SG11201610432UA - Formulated receptor polypeptides and related methods - Google Patents
Formulated receptor polypeptides and related methodsInfo
- Publication number
- SG11201610432UA SG11201610432UA SG11201610432UA SG11201610432UA SG11201610432UA SG 11201610432U A SG11201610432U A SG 11201610432UA SG 11201610432U A SG11201610432U A SG 11201610432UA SG 11201610432U A SG11201610432U A SG 11201610432UA SG 11201610432U A SG11201610432U A SG 11201610432UA
- Authority
- SG
- Singapore
- Prior art keywords
- formulated
- related methods
- receptor polypeptides
- polypeptides
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462012104P | 2014-06-13 | 2014-06-13 | |
| US201462047995P | 2014-09-09 | 2014-09-09 | |
| US201462058789P | 2014-10-02 | 2014-10-02 | |
| US201562142812P | 2015-04-03 | 2015-04-03 | |
| PCT/US2015/035818 WO2015192127A2 (en) | 2014-06-13 | 2015-06-15 | Formulated receptor polypeptides and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201610432UA true SG11201610432UA (en) | 2017-01-27 |
Family
ID=54834575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610432UA SG11201610432UA (en) | 2014-06-13 | 2015-06-15 | Formulated receptor polypeptides and related methods |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20170202909A1 (en) |
| EP (1) | EP3155008B1 (en) |
| JP (1) | JP2017519009A (en) |
| KR (1) | KR20170035891A (en) |
| CN (1) | CN107074931A (en) |
| AP (1) | AP2016009647A0 (en) |
| AU (1) | AU2015274293A1 (en) |
| BR (1) | BR112016029211A2 (en) |
| CA (1) | CA2952231A1 (en) |
| CL (1) | CL2016003191A1 (en) |
| EA (1) | EA201692568A1 (en) |
| IL (1) | IL249373A0 (en) |
| MX (1) | MX2016016281A (en) |
| PE (1) | PE20170471A1 (en) |
| PH (1) | PH12016502479A1 (en) |
| SG (1) | SG11201610432UA (en) |
| TN (1) | TN2016000551A1 (en) |
| TW (1) | TW201625675A (en) |
| WO (1) | WO2015192127A2 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| KR20160137665A (en) | 2005-11-23 | 2016-11-30 | 악셀레론 파마 인코포레이티드 | Activin-actrπa antagonists and uses for promoting bone growth |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| AU2008211007B2 (en) | 2007-02-01 | 2013-09-19 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for treating or preventing breast cancer |
| TW202021980A (en) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | Variants derived from actriib and uses therefor |
| CA3039330C (en) | 2007-02-09 | 2021-11-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| CN107412734A (en) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | Activin A CTRIIA antagonists and the purposes for reducing or suppressing FSH secretions |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| JP5922928B2 (en) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | Use of GDF traps to increase red blood cell levels |
| EP2440576A4 (en) | 2009-06-08 | 2013-11-20 | Acceleron Pharma Inc | Methods for increasing thermogenic adipocytes |
| AU2010263182B2 (en) | 2009-06-12 | 2016-05-12 | Acceleron Pharma Inc. | Truncated ActRIIB-Fc fusion proteins |
| CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| ES2884095T3 (en) | 2012-11-02 | 2021-12-10 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| MX2015009901A (en) | 2013-02-01 | 2016-04-06 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject. |
| BR122023023170A2 (en) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | USE OF AN ACTRII ANTAGONIST IN THE TREATMENT OR PREVENTION OF SKIN ULCERS ASSOCIATED WITH BETA-THALASSEMIA |
| EP3878857A1 (en) | 2015-04-22 | 2021-09-15 | Biogen MA Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| CN110430890A (en) | 2016-11-10 | 2019-11-08 | 科乐斯疗法公司 | Activin receptor IIA type variant and its application method |
| WO2019049967A1 (en) * | 2017-09-07 | 2019-03-14 | Ｊｃｒファーマ株式会社 | Aqueous pharmaceutical composition |
| EP3706777A4 (en) | 2017-11-09 | 2021-06-23 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| AU2019206634A1 (en) | 2018-01-12 | 2020-07-23 | Keros Therapeutics, Inc. | Activin receptor type IIB variants and methods of use thereof |
| US11357726B2 (en) * | 2018-08-29 | 2022-06-14 | Translate Bio, Inc. | Process of preparing mRNA-loaded lipid nanoparticles |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| EP0088046B1 (en) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
| EP1129190B2 (en) | 1998-11-13 | 2017-01-11 | Immunex Corporation | Human tslp dna and polypeptides |
| JP4038118B2 (en) | 2002-11-29 | 2008-01-23 | 株式会社コガネイ | Fluid pressure cylinder |
| JO3324B1 (en) * | 2006-04-21 | 2019-03-13 | Amgen Inc | Lyophilized Therapeutic Peptibody Formulations |
| US7947646B2 (en) * | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| MX2010007728A (en) * | 2008-01-15 | 2010-12-21 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same. |
| PE20120206A1 (en) * | 2008-11-26 | 2012-03-09 | Amgen Inc | ACTIVIN IIB RECEPTOR POLYPEPTIDE VARIANTS |
| CN102946858B (en) * | 2010-05-10 | 2015-09-30 | 英塔斯制药有限公司 | The liquid preparation of the polypeptide containing immunoglobulin Fc |
| JP5782185B2 (en) | 2012-06-01 | 2015-09-24 | 日本電信電話株式会社 | Packet transfer processing method and packet transfer processing device |
| MX2015009901A (en) * | 2013-02-01 | 2016-04-06 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject. |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| WO2016205370A1 (en) * | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
-
2015
- 2015-06-15 BR BR112016029211A patent/BR112016029211A2/en not_active Application Discontinuation
- 2015-06-15 CN CN201580043173.4A patent/CN107074931A/en active Pending
- 2015-06-15 AP AP2016009647A patent/AP2016009647A0/en unknown
- 2015-06-15 JP JP2016572730A patent/JP2017519009A/en active Pending
- 2015-06-15 KR KR1020177001016A patent/KR20170035891A/en unknown
- 2015-06-15 US US15/316,767 patent/US20170202909A1/en not_active Abandoned
- 2015-06-15 SG SG11201610432UA patent/SG11201610432UA/en unknown
- 2015-06-15 PE PE2016002711A patent/PE20170471A1/en not_active Application Discontinuation
- 2015-06-15 CA CA2952231A patent/CA2952231A1/en active Pending
- 2015-06-15 TN TN2016000551A patent/TN2016000551A1/en unknown
- 2015-06-15 TW TW104119310A patent/TW201625675A/en unknown
- 2015-06-15 AU AU2015274293A patent/AU2015274293A1/en not_active Abandoned
- 2015-06-15 WO PCT/US2015/035818 patent/WO2015192127A2/en active Application Filing
- 2015-06-15 EP EP15805829.7A patent/EP3155008B1/en active Active
- 2015-06-15 EA EA201692568A patent/EA201692568A1/en unknown
- 2015-06-15 MX MX2016016281A patent/MX2016016281A/en unknown
-
2016
- 2016-12-04 IL IL249373A patent/IL249373A0/en unknown
- 2016-12-12 PH PH12016502479A patent/PH12016502479A1/en unknown
- 2016-12-13 CL CL2016003191A patent/CL2016003191A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3155008B1 (en) | 2020-08-26 |
| CA2952231A1 (en) | 2015-12-17 |
| IL249373A0 (en) | 2017-02-28 |
| EA201692568A1 (en) | 2017-05-31 |
| PH12016502479A1 (en) | 2017-04-10 |
| AP2016009647A0 (en) | 2016-12-31 |
| EP3155008A4 (en) | 2018-05-16 |
| CL2016003191A1 (en) | 2017-11-10 |
| PE20170471A1 (en) | 2017-05-14 |
| BR112016029211A2 (en) | 2018-01-30 |
| EP3155008A2 (en) | 2017-04-19 |
| CN107074931A (en) | 2017-08-18 |
| WO2015192127A2 (en) | 2015-12-17 |
| US20170202909A1 (en) | 2017-07-20 |
| AU2015274293A1 (en) | 2017-02-02 |
| TW201625675A (en) | 2016-07-16 |
| MX2016016281A (en) | 2017-03-31 |
| WO2015192127A3 (en) | 2016-03-17 |
| TN2016000551A1 (en) | 2018-04-04 |
| KR20170035891A (en) | 2017-03-31 |
| JP2017519009A (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275307B (en) | Syntac polypeptides and uses thereof | |
| IL249373A0 (en) | Formulated receptor polypeptides and related methods | |
| IL285403A (en) | Mhc class i epitope delivering polypeptides | |
| HK1255067A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
| HK1243440A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| GB201514875D0 (en) | Receptor | |
| HUE045307T2 (en) | Anti-egfrviii antibodies and uses thereof | |
| HK1252163A1 (en) | Receptor | |
| FI3169703T4 (en) | Chimeric antigen receptor and its use | |
| IL247315A0 (en) | Anti-acth antibodies and use thereof | |
| IL246499A0 (en) | Epicutaneous immunorebalancing | |
| ZA201701348B (en) | New polypeptides | |
| GB201410031D0 (en) | Polypeptides and uses thereof | |
| PL3347376T3 (en) | Novel igfr-like receptor and uses thereof | |
| HK1219454A1 (en) | Portable object for regattas | |
| IL246533A0 (en) | Novel polypeptides | |
| EP2978089C0 (en) | Chute | |
| GB201403024D0 (en) | Polypeptides | |
| GB201419237D0 (en) | Novel polypeptides | |
| GB201400508D0 (en) | Mutant polypeptides | |
| GB201410265D0 (en) | Novel polypeptides | |
| GB201401973D0 (en) | Antibody polypeptides and uses thereof |